194 related articles for article (PubMed ID: 36275712)
21. IL-21 Increases the Reactivity of Allogeneic Human Vγ9Vδ2 T Cells Against Primary Glioblastoma Tumors.
Joalland N; Chauvin C; Oliver L; Vallette FM; Pecqueur C; Jarry U; Scotet E
J Immunother; 2018 Jun; 41(5):224-231. PubMed ID: 29683891
[TBL] [Abstract][Full Text] [Related]
22. Low-Density Lipoprotein Uptake Inhibits the Activation and Antitumor Functions of Human Vγ9Vδ2 T Cells.
Rodrigues NV; Correia DV; Mensurado S; Nóbrega-Pereira S; deBarros A; Kyle-Cezar F; Tutt A; Hayday AC; Norell H; Silva-Santos B; Dias S
Cancer Immunol Res; 2018 Apr; 6(4):448-457. PubMed ID: 29358174
[TBL] [Abstract][Full Text] [Related]
23. DNAX accessory molecule-1 (CD226) promotes human hepatocellular carcinoma cell lysis by Vgamma9Vdelta2 T cells.
Toutirais O; Cabillic F; Le Friec G; Salot S; Loyer P; Le Gallo M; Desille M; de La Pintière CT; Daniel P; Bouet F; Catros V
Eur J Immunol; 2009 May; 39(5):1361-8. PubMed ID: 19404979
[TBL] [Abstract][Full Text] [Related]
24. Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer.
Xu Y; Xiang Z; Alnaggar M; Kouakanou L; Li J; He J; Yang J; Hu Y; Chen Y; Lin L; Hao J; Li J; Chen J; Li M; Wu Q; Peters C; Zhou Q; Li J; Liang Y; Wang X; Han B; Ma M; Kabelitz D; Xu K; Tu W; Wu Y; Yin Z
Cell Mol Immunol; 2021 Feb; 18(2):427-439. PubMed ID: 32939032
[TBL] [Abstract][Full Text] [Related]
25. Expansion With IL-15 Increases Cytotoxicity of Vγ9Vδ2 T Cells and Is Associated With Higher Levels of Cytotoxic Molecules and T-bet.
Aehnlich P; Carnaz Simões AM; Skadborg SK; Holmen Olofsson G; Thor Straten P
Front Immunol; 2020; 11():1868. PubMed ID: 32983105
[TBL] [Abstract][Full Text] [Related]
26. Upregulation of the mevalonate pathway by cholesterol depletion abolishes tolerance to N-bisphosphonate induced Vγ9Vδ2 T cell cytotoxicity in PC-3 prostate cancer cells.
Arkko S; Zlatev HP; Mönkkönen H; Räikkönen J; Benzaïd I; Clézardin P; Mönkkönen J; Määttä JA
Cancer Lett; 2015 Feb; 357(1):279-285. PubMed ID: 25444923
[TBL] [Abstract][Full Text] [Related]
27. Cytokine-mediated activation of human ex vivo-expanded Vγ9Vδ2 T cells.
Domae E; Hirai Y; Ikeo T; Goda S; Shimizu Y
Oncotarget; 2017 Jul; 8(28):45928-45942. PubMed ID: 28521284
[TBL] [Abstract][Full Text] [Related]
28. Dendritic cells modified by tumor associated antigen SMP30 have enhanced antitumor effect against mouse hepatocarcinoma cells in vitro and in vivo.
Guo J; Zhang Y; Qin Q; Chao N; Huang T; Chen C; Lu X; Huang R; Pan J
Am J Transl Res; 2022; 14(8):5785-5799. PubMed ID: 36105050
[TBL] [Abstract][Full Text] [Related]
29. Vγ9Vδ2 T Cells Concurrently Kill Cancer Cells and Cross-Present Tumor Antigens.
Holmen Olofsson G; Idorn M; Carnaz Simões AM; Aehnlich P; Skadborg SK; Noessner E; Debets R; Moser B; Met Ö; Thor Straten P
Front Immunol; 2021; 12():645131. PubMed ID: 34149689
[TBL] [Abstract][Full Text] [Related]
30. Gamma Delta T Cell Therapy for Cancer: It Is Good to be Local.
Pauza CD; Liou ML; Lahusen T; Xiao L; Lapidus RG; Cairo C; Li H
Front Immunol; 2018; 9():1305. PubMed ID: 29937769
[TBL] [Abstract][Full Text] [Related]
31. Potentiation of antigen-stimulated V gamma 9V delta 2 T cell cytokine production by immature dendritic cells (DC) and reciprocal effect on DC maturation.
Devilder MC; Maillet S; Bouyge-Moreau I; Donnadieu E; Bonneville M; Scotet E
J Immunol; 2006 Feb; 176(3):1386-93. PubMed ID: 16424165
[TBL] [Abstract][Full Text] [Related]
32. Chemokine receptors expression and migration potential of tumor-infiltrating and peripheral-expanded Vgamma9Vdelta2 T cells from renal cell carcinoma patients.
Viey E; Lucas C; Romagne F; Escudier B; Chouaib S; Caignard A
J Immunother; 2008 Apr; 31(3):313-23. PubMed ID: 18317356
[TBL] [Abstract][Full Text] [Related]
33. Antigen-Presenting Cell Characteristics of Human γδ T Lymphocytes in Chronic Myeloid Leukemia.
Sawaisorn P; Tangchaikeeree T; Chan-On W; Leepiyasakulchai C; Udomsangpetch R; Hongeng S; Jangpatarapongsa K
Immunol Invest; 2019 Jan; 48(1):11-26. PubMed ID: 30321079
[TBL] [Abstract][Full Text] [Related]
34. Preferential Th1 cytokine profile of phosphoantigen-stimulated human Vγ9Vδ2 T cells.
Dunne MR; Mangan BA; Madrigal-Estebas L; Doherty DG
Mediators Inflamm; 2010; 2010():704941. PubMed ID: 21403900
[TBL] [Abstract][Full Text] [Related]
35. A Bispecific γδ T-cell Engager Targeting EGFR Activates a Potent Vγ9Vδ2 T cell-Mediated Immune Response against EGFR-Expressing Tumors.
King LA; Toffoli EC; Veth M; Iglesias-Guimarais V; Slot MC; Amsen D; van de Ven R; Derks S; Fransen MF; Tuynman JB; Riedl T; Roovers RC; Adang AEP; Ruben JM; Parren PWHI; de Gruijl TD; van der Vliet HJ
Cancer Immunol Res; 2023 Sep; 11(9):1237-1252. PubMed ID: 37368791
[TBL] [Abstract][Full Text] [Related]
36. Human Umbilical Cord Mesenchymal Stem Cells Inhibit the Function of Allogeneic Activated Vγ9Vδ2 T Lymphocytes In Vitro.
Liu X; Feng T; Gong T; Shen C; Zhu T; Wu Q; Li Q; Li H
Biomed Res Int; 2015; 2015():317801. PubMed ID: 25984529
[TBL] [Abstract][Full Text] [Related]
37. Repeated systemic administrations of both aminobisphosphonates and human Vγ9Vδ2 T cells efficiently control tumor development in vivo.
Santolaria T; Robard M; Léger A; Catros V; Bonneville M; Scotet E
J Immunol; 2013 Aug; 191(4):1993-2000. PubMed ID: 23836057
[TBL] [Abstract][Full Text] [Related]
38. Combining Vγ9Vδ2 T Cells with a Lipophilic Bisphosphonate Efficiently Kills Activated Hepatic Stellate Cells.
Zhou X; Gu Y; Xiao H; Kang N; Xie Y; Zhang G; Shi Y; Hu X; Oldfield E; Zhang X; Zhang Y
Front Immunol; 2017; 8():1381. PubMed ID: 29118758
[TBL] [Abstract][Full Text] [Related]
39. N6-isopentenyladenosine, an endogenous isoprenoid end product, directly affects cytotoxic and regulatory functions of human NK cells through FDPS modulation.
Ciaglia E; Pisanti S; Picardi P; Laezza C; Malfitano AM; D'Alessandro A; Gazzerro P; Vitale M; Carbone E; Bifulco M
J Leukoc Biol; 2013 Dec; 94(6):1207-19. PubMed ID: 23847096
[TBL] [Abstract][Full Text] [Related]
40. Mechanisms of the antitumor activity of human Vγ9Vδ2 T cells in combination with zoledronic acid in a preclinical model of neuroblastoma.
Di Carlo E; Bocca P; Emionite L; Cilli M; Cipollone G; Morandi F; Raffaghello L; Pistoia V; Prigione I
Mol Ther; 2013 May; 21(5):1034-43. PubMed ID: 23481325
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
